Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms.
Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms.
复制标题
DOI：
10.2217/fca.12.71
复制
发表时间：
2013-01
影响因子：
1.7
通讯作者：
Shi GP
中科院分区：
文献类型：
--
作者：
Qin Y;Cao X;Yang Y;Shi GP
半胱氨酸蛋白酶组织蛋白酶和基质金属蛋白酶都与人类和动物腹主动脉瘤（AAA）的发病机制有关。来自患有AAA的人或动物的血液和主动脉组织含有比来自健康受试者的血液和主动脉组织高得多的水平的这些蛋白酶，并且其内源性抑制剂的水平通常较低。蛋白酶和蛋白酶促因子缺陷小鼠和合成蛋白酶抑制剂已经证实，半胱氨酰组织蛋白酶和基质金属蛋白酶都直接参与AAA的发展在几个实验模型系统。在这里，我们总结了我们目前对蛋白酶如何促进AAA发病机制的理解，并讨论了蛋白酶或其抑制剂是否可作为这种常见的人类动脉疾病的诊断生物标志物或潜在的治疗靶点。
Both cysteine protease cathepsins and matrix metalloproteinases are implicated in the pathogenesis of abdominal aortic aneurysms (AAAs) in humans and animals. Blood and aortic tissues from humans or animals with AAAs contain much higher levels of these proteases, and often lower levels of their endogenous inhibitors, than do blood and aortic tissues from healthy subjects. Protease- and protease inhibitor-deficient mice and synthetic protease inhibitors have affirmed that cysteinyl cathepsins and matrix metalloproteinases both participate directly in AAA development in several experimental model systems. Here, we summarize our current understanding of how proteases contribute to the pathogenesis of AAA, and discuss whether proteases or their inhibitors may serve as diagnostic biomarkers or potential therapeutic targets for this common human arterial disease.